How Does Spravato Work in the Brain? A Plain English Guide
When you are considering Spravato for treatment resistant depression, you naturally want to understand what the medication is actually doing inside your head. Most psychiatric medications come with vague explanations about chemical imbalances, and after a few of those explanations, the words start to feel meaningless. Patients tell us they want to know the real story, not a marketing summary. At Serenada Mental Health in Georgetown and Waco, Texas, we believe patients deserve a clear, honest explanation of the science behind the treatments we offer.
So, how does Spravato work in the brain? The short answer is that Spravato, the brand name for esketamine, acts on a completely different neurotransmitter system than traditional antidepressants. Instead of targeting serotonin or norepinephrine, it works on glutamate, the most abundant excitatory neurotransmitter in the brain. By blocking a specific receptor called the NMDA receptor, esketamine triggers a cascade that promotes the growth of new neural connections, a process called neuroplasticity. This is fundamentally different from the way SSRIs work, and it helps explain why Spravato can produce improvements in days rather than the weeks required by older medications. In this article we will walk through the glutamate system, the NMDA receptor, what happens at the cellular level, and why this mechanism matters for people living with treatment resistant depression.
The Old Story: Serotonin and the Monoamine Hypothesis
To understand what makes Spravato different, it helps to start with the older story. For decades, the dominant theory of depression was the monoamine hypothesis. According to this view, depression was caused largely by a deficiency in neurotransmitters like serotonin, norepinephrine, and dopamine. Medications like SSRIs were designed to increase the availability of these neurotransmitters in the brain by preventing their reuptake. The theory made intuitive sense, and the medications did help many people. But the theory never fully explained depression, and it left significant gaps.
The most obvious gap was timing. If depression is caused by low serotonin, and SSRIs raise serotonin levels within hours of the first dose, why do patients typically wait four to six weeks before feeling any improvement? The answer, which researchers began to piece together in the 1990s and 2000s, is that the antidepressant effect is not really about the neurotransmitter levels themselves. It is about downstream changes in the brain, including the growth of new neurons and new synaptic connections, that take weeks to develop. This insight redirected the field. If the goal is to promote neural growth and rewiring, then perhaps targeting the systems that directly regulate neural plasticity would work faster than nudging serotonin levels. That is exactly the insight that led researchers to glutamate, and ultimately to ketamine and esketamine.
The Glutamate System: A Different Pathway
Glutamate is the most abundant excitatory neurotransmitter in the human brain. It is the chemical that neurons use to send activating signals to other neurons, and it is involved in virtually every brain function, including learning, memory, mood regulation, and cognition. Roughly half of all synapses in the brain use glutamate. Despite its importance, glutamate received relatively little attention in psychiatric drug development for decades, partly because the system is so widespread that manipulating it without causing dangerous side effects seemed nearly impossible.
That changed when researchers noticed that ketamine, an anesthetic that acts on glutamate receptors, produced rapid antidepressant effects in patients who had not responded to other treatments. The discovery was almost accidental, but it opened a new frontier. Subsequent research showed that the glutamate system and depression are closely linked. Chronic stress, which is a major risk factor for depression, appears to disrupt glutamate signaling in key brain regions, particularly the prefrontal cortex and the hippocampus. In depression, synaptic density in these regions measurably decreases. The brain literally loses connections in the areas responsible for mood regulation, memory, and executive function. Restoring those connections, rather than just adjusting serotonin levels, became the new goal. Esketamine was developed specifically to target this pathway.
The NMDA Receptor: Where Spravato Acts
To understand how Spravato works in the brain, we need to zoom in one more level, to the receptor where the medication actually binds. Glutamate acts on several types of receptors, but the one most relevant to esketamine is the NMDA receptor. The NMDA receptor is named using a scientific abbreviation for a synthetic activating compound, but the receptor's natural job is to respond to glutamate. It plays a central role in synaptic plasticity, learning, and memory.
Spravato is an NMDA receptor antagonist, which means it blocks the receptor rather than activating it. This might seem counterintuitive. If glutamate is good for neural connections, why would blocking its receptor help depression? The answer lies in the cascade that blocking triggers. When esketamine blocks NMDA receptors on certain interneurons, it disrupts a feedback loop that normally keeps glutamate release in check. With the brake lifted, glutamate release surges in the prefrontal cortex. This surge activates another receptor, called the AMPA receptor, which is the key that unlocks the next step in the cascade. Without AMPA receptor activation, esketamine does not produce its antidepressant effects, a finding confirmed by research showing that blocking AMPA receptors prevents esketamine from working. The whole mechanism is a beautifully orchestrated chain reaction.
BDNF and Synaptogenesis: Rebuilding the Brain
The AMPA receptor surge triggered by esketamine leads to the release of a protein called brain derived neurotrophic factor, or BDNF. BDNF is often described as fertilizer for the brain. It promotes the survival of existing neurons, encourages the growth of new ones, and stimulates the formation of new synapses between neurons. In other words, BDNF is the molecular signal that tells the brain to build new connections. The link between BDNF and neuroplasticity is one of the most consistent findings in modern psychiatric research.
When esketamine triggers a surge in BDNF, the result is a rapid increase in synaptogenesis, the formation of new synapses. Animal studies have shown that within hours of ketamine or esketamine administration, new synaptic spines begin to form on neurons in the prefrontal cortex. These are the physical connections through which neurons communicate, and their formation reverses the synaptic loss that chronic stress and depression had caused. This is not a metaphor. It is a measurable structural change in the brain. For patients living with the cognitive and emotional fog of treatment resistant depression, the implication is profound. Spravato is not just adjusting the levels of existing chemicals. It is helping the brain rebuild the connections that depression has eroded.
Why This Mechanism Matters for Treatment Resistant Depression
Understanding the mechanism helps explain why Spravato is particularly valuable for patients with treatment resistant depression. If you have tried two or more antidepressants without meaningful relief, the problem may not be that your serotonin system is unresponsive. It may be that the depression is being maintained by structural changes in the brain that serotonin based medications cannot fully address. No amount of additional serotonin will rebuild synapses that have been lost. But a medication that directly promotes synaptogenesis, like esketamine, can.
This is also why Spravato often works faster than traditional antidepressants. SSRIs ultimately do promote some degree of neuroplasticity, which is why they take weeks to work. The serotonin increase is just the upstream trigger for slower downstream changes. Esketamine skips the upstream step and directly stimulates the downstream machinery of synaptogenesis within hours. Clinical studies have shown response rates around 60 percent and remission rates near 52 percent for patients with treatment resistant depression, often within the first week of treatment. For patients who have waited months or years for relief, that timing is not just clinically significant. It is life changing. To understand how these options fit within the broader landscape of care, see our guide to advanced treatment options for depression.
What Happens During and After a Spravato Session
The mechanism we have just described does not happen in a vacuum. It happens in the context of a structured clinical session, and the way the session is designed supports the medication's effects. Spravato is administered as a nasal spray in a REMS certified clinic under the direct supervision of a healthcare provider. Within minutes of administration, patients often begin to feel the effects of the medication, which can include a sense of dissociation, mild sedation, or changes in perception. These effects typically peak within the first 40 minutes and resolve within the two hour observation period that follows every dose.
The dissociative experience, while sometimes unsettling for first time patients, appears to be related to the same NMDA receptor activity that drives the antidepressant effects. Researchers continue to study whether the subjective experience of dissociation is itself therapeutically important or simply a side effect of the receptor activity. What is clear is that the neuroplastic changes triggered by the medication create a window of heightened receptivity to new learning in the hours and days following each dose. This is why combining Spravato with psychotherapy produces more durable outcomes than medication alone. The medication opens the door, and therapy walks through it. To walk through every detail of what a session involves, our guide to what actually happens during a Spravato session covers the entire experience from arrival to discharge.
How Spravato Compares to SSRIs at the Brain Level
When patients ask us how does Spravato work in the brain compared to the medications they have already tried, the simplest way to summarize the difference is this. SSRIs work upstream, slowly, and indirectly. Spravato works downstream, rapidly, and directly. SSRIs increase the availability of serotonin in the synaptic cleft, and over weeks, this leads to downstream changes in receptor sensitivity and eventually to some degree of neuroplasticity. Spravato blocks NMDA receptors, triggers a glutamate surge, releases BDNF, and promotes synaptogenesis within hours.
Both medications can be effective, and they are often used together. Spravato is FDA approved as an adjunct to an oral antidepressant, not as a standalone treatment. The two approaches complement each other. The oral antidepressant provides a steady foundation of neurotransmitter support, while Spravato provides the rapid structural rebuilding that depression has prevented. This combination approach is the standard of care for treatment resistant depression because it addresses both the chemical and structural dimensions of the illness. You can read more about our overall approach on our Spravato treatment service page.
What the Mechanism Does Not Do
Honesty requires acknowledging what Spravato does not do. Despite the impressive mechanism, Spravato is not a cure. The neuroplastic changes it triggers are powerful, but they are not permanent without ongoing treatment and the active work of recovery. Most patients require a maintenance phase with sessions every two weeks or monthly to sustain the gains made during induction. The medication also does not address the psychological, social, and environmental factors that contribute to depression. It can create the biological conditions for healing, but the patient and their care team still have to do the work of building a life worth living around those conditions.
It is also worth noting that the mechanism we have described, while supported by substantial research, is not fully understood. Neuroscience is still working out the details of how esketamine produces its effects, and some aspects of the cascade may be more complex than current models suggest. Humility about what we do not yet know is part of ethical psychiatric care. What we can say with confidence is that the evidence supports Spravato as a meaningfully different and effective option for adults with treatment resistant depression, and that the mechanism is grounded in real neuroscience rather than marketing.
Accessing Spravato Treatment in Central Texas
For adults in Central Texas, accessing REMS certified esketamine therapy has become significantly easier in recent years. Serenada Mental Health offers Spravato treatment at both our Georgetown and Waco clinics, bringing interventional psychiatry closer to home for residents across the region. Whether you live in Georgetown, Waco, Round Rock, Temple, Belton, or the rural communities in between, qualified care is now within reach.
We accept a broad range of insurance, including Medicare, TriWest and TriCare, and ChampVA, which is particularly important for veterans and military families in our region who are disproportionately affected by treatment resistant depression. For patients whose schedules or locations make regular in person visits challenging, our telehealth psychiatry in Texas offering extends much of the surrounding care into the home. While the Spravato doses themselves must be administered in person under clinical supervision, psychiatric follow up, medication management, and much of the psychotherapy can be delivered securely by video.
The Bottom Line on How Spravato Works in the Brain
So, how does Spravato work in the brain? The clearest one sentence summary is this. Spravato blocks NMDA receptors, which triggers a glutamate surge, which activates AMPA receptors, which releases BDNF, which stimulates the growth of new synaptic connections in brain regions that depression has damaged. That cascade is the mechanism behind the rapid antidepressant effects that have made Spravato one of the most significant advances in psychiatric pharmacotherapy in decades.
If you have been living with treatment resistant depression, understanding the mechanism matters because it gives you a framework for understanding why this treatment might work where others have not. It is not magic. It is neuroscience, applied carefully and ethically, in the context of a comprehensive treatment plan. The brain that has been stuck in depression is not broken beyond repair. It is, in many cases, waiting for the right biological signal to begin rebuilding. Spravato provides that signal. The work of recovery, supported by therapy, lifestyle changes, and ongoing psychiatric care, is what turns that signal into lasting relief.
Take the Next Step Toward Understanding and Relief
At Serenada Mental Health, we believe that patients deserve more than vague explanations and prescription pads. You deserve to understand what is happening in your brain, why a particular treatment is being recommended, and what to expect at every step. Our team practices integrative, trauma informed, culturally sensitive psychiatry, and we are happy to walk through the science, the logistics, and the financial details of Spravato treatment with you in detail. Where healing begins with understanding, and where your questions are taken seriously rather than dismissed.
Call us at (512) 612-9441 or click Book Now to schedule a comprehensive consultation at our Georgetown or Waco clinic. The clarity you have been looking for starts with a single conversation, and we would be honored to have it with you.